Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

Blood

Volumn 119, Issue 9, 2012, Pages 2074-2082

  Tai, Yu Tzu ^a   Horton, Holly M ^b   Kong, Sun Young ^a,c   Pong, Erik ^b   Chen, Hsing ^b   Cemerski, Saso ^b   Bernett, Matthew J ^b   Nguyen, Duc Hanh T ^b   Karki, Sher ^b   Chu, Seung Y ^b   Lazar, Greg A ^b   Munshi, Nikhil C ^a,d   Desjarlais, John R ^b   Anderson, Kenneth C ^a   Muchhal, Umesh S ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Xencor Inc   (United States)

^c National Cancer Center   (South Korea)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; FC RECEPTOR; GRANZYME B; IMMUNOGLOBULIN G1 ANTIBODY; LENALIDOMIDE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BONE MARROW; CANCER INHIBITION; CELL LINE; CELL SURFACE; DRUG POTENTIATION; FEMALE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SINGLE DRUG DOSE; TUMOR GROWTH; XENOGRAFT;

EID: 84863251086     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-364521     Document Type: Article

References (50)

1. Ellis JH, Barber KA, Tutt A, et al. Engineered anti- CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J Immunol. 1995;155(2): 925-937.
2. Korte W, Jost C, Cogliatti S, Hess U, Cerny T. Accelerated progression of multiple myeloma during anti-CD20 (rituximab) therapy. Ann Oncol. 1999; 10(10):1249-1250. (Pubitemid 29533578)
3. Treon SP, Pilarski LM, Belch AR, et al. CD20- directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002;25(1):72-81. (Pubitemid 34052837)
4. Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65(13):5898-5906. (Pubitemid 40911196)
5. Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005;65(24):11712-11720. (Pubitemid 41821732)
6. Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zole-dronic acid on multiple myeloma cells. Int J Oncol. 2002;21(4):867-873.
7. Ozaki S, Kosaka M, Wakahara Y, et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood. 1999;93(11): 3922-3930. (Pubitemid 29249841)
8. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13(18): 5556s-5563s. (Pubitemid 47510387)
9. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, et al. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood. 2006;108(4):1346-1352. (Pubitemid 44232035)
10. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329-1337.
11. Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3- mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004;64(13):4629-4636. (Pubitemid 38856937)
12. Ikeda H, Hideshima T, Fulciniti M, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009;15(12): 4028-4037.
13. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994;84(6): 1922-1930. (Pubitemid 24286144)
14. Ohtomo T, Sugamata Y, Ozaki Y, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun. 1999;258(3):583-591. (Pubitemid 29290312)
15. Kawai S, Yoshimura Y, Iida S, et al. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol Rep. 2006;15(2):361-367.
16. Ono K, Ohtomo T, Yoshida K, et al. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol Immunol. 1999;36(6):387-395. (Pubitemid 29331647)
17. Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood. 1997;90(8):3179-3186. (Pubitemid 27444214)
18. Cai D, Cao J, Li Z, et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer. 2009;9:102.
19. Kawai S, Azuma Y, Fujii E, et al. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci. 2008;99(12):2461-2466.
20. Schliemann C, Roesli C, Kamada H, et al. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood. 2010;115(3):736-744.
21. Wang W, Nishioka Y, Ozaki S, et al. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother. 2009;58(6):967- 976.
22. Wang W, Nishioka Y, Ozaki S, et al. Chimeric and humanized anti-HM1.24 antibodies mediate antibody- dependent cellular cytotoxicity against lung cancer cells. Lung Cancer. 2009;63(1):23-31.
23. Powles R, Sirohi B, Morgan G, et al. A Phase i study of the safety, tolerance, pharmacokinetics, antigenicity and efficacy of a single intravenous dose of AHM followed by multiple doses of intravenous AHM in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2001;98: 165a. (Pubitemid 33786149)
24. Repka T, Chiorean EG, Gay J, et al. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res. 2003;9(7):2440-2446. (Pubitemid 36842083)
25. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21): 3940-3947. (Pubitemid 46606207)
26. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007;25(24):3712-3718. (Pubitemid 47372612)
27. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008; 26(11):1789-1796.
28. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11): 4005-4010.
29. Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti- CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68(19):8049- 8057.
30. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008;7(8):2517-2527.
31. Zalevsky J, Leung IW, Karki S, et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood. 2009; 113(16):3735-3743.
32. Horton HM, Bernett MJ, Peipp M, et al. Fcengineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood. 2010;116(16):3004- 3012.
33. Blum KA, Smith M, Fung H, et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol (ASCO Meeting Abstracts). 2009;27(15S):Abstract 8531.
34. Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol. 2007;44(8):1986- 1998.
35. Kim K, Kong SY, Fulciniti M, et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010;149(4):537-549.
36. Oflazoglu E, Stone IJ, Brown L, et al. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer. 2009;100(1):113-117.
37. Fischer L, Penack O, Gentilini C, et al. The antilymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol. 2006;34(6):753-759. (Pubitemid 43737097)
38. Sirohi B, Powles R. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2009;9(11): 1559-1570.
39. Watanabe K, Watanabe R, Shioda A, Mizoguchi K, Sugimoto T, Terao K. Investigation of the mechanism of drug-induced autoimmune hemolytic anemia in cynomolgus monkeys elicited by a repeated-dose of a humanized monoclonal antibody drug. J Toxicol Sci. 2003;28(3):123-138. (Pubitemid 37129062)
40. Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009;20(6):685-691.
41. Ishiguro T, Kawai S, Habu K, et al. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients. Cancer Sci. 2010;101(10): 2227-2233.
42. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002; 277(30):26733-26740. (Pubitemid 34951677)
43. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
44. Hundemer M, Schmidt S, Condomines M, et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol. 2006;34(4): 486-496.
45. Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab- treated CD20+ tumor cells. Clin Cancer Res. 2008;14(14):4650-4657.
46. Lonial S, Vij R, Harousseau J-L, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/ refractory multiple myeloma: interim results of a phase 1 study. ASH Annual Meeting Abstracts. 2010;116(21):1936.
47. Richardson PG, Moreau P, Jakubowiak AJ, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: interim results of a phase 2 study. ASH Annual Meeting Abstracts. 2010;116(21):986.
48. Neuber B, Herth I, Tolliver C, et al. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol. 2011;187(2):1047-1056.
49. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
50. Amano J, Masuyama N, Hirota Y, et al. Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody. Drug Metab Dispos. 2010; 38(12):2339-2346.